Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bortezomib + dexamethasone + rituximab
- Development stage
- Phase 2
- Lead developer
- Takeda
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
A combination regimen consisting of bortezomib (a proteasome inhibitor), dexamethasone (a corticosteroid), and rituximab (an anti-CD20 monoclonal antibody). This chemo-free, fixed duration treatment works through multiple mechanisms to target cancer cells in hematological malignancies. Bortezomib blocks proteasomes, causing protein buildup in cancer cells leading to cell death; dexamethasone provides anti-inflammatory and immunosuppressive effects; and rituximab targets CD20 antigen on B cells.
- Other names
- BDR
02
Targets
PSMB1 (26S Proteasome (β1-Subunit))PSMB5 (Proteasome subunit beta Type-5)CD20 (B-lymphocyte antigen CD20)GR (Glucocorticoid receptor)PSMB9 (Immunoproteasome subunit beta type-1i)
Beyond the preview
Go deeper on bortezomib + dexamethasone + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bortezomib + dexamethasone + rituximab.